{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:19:42Z","timestamp":1778757582710,"version":"3.51.4"},"reference-count":104,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Among patients with advanced prostate cancer (aPC), fatigue is a commonly experienced symptom that may be associated with the disease itself or occur as a side effect of treatment. We aimed to develop evidence-based, consensus-driven statements to support shared decision-making for managing fatigue in patients with aPC.\n                    <jats:bold>Methods:<\/jats:bold>\n                    To identify potential fatigue-management strategies, we performed a targeted literature review followed by expert advisor interviews, and then conducted a modified Delphi panel. In both the interviews and the modified Delphi panel, participants included oncologists, urologists, exercise scientists, psychologists, nutritionists\/dietitians, and nurse practitioners\/nurses. The modified Delphi panel comprised 2 survey rounds, with a live panel discussion between them, intended to drive consensus on the statements. In determining consensus for the final statements, each strategy\u2019s effectiveness, accessibility for patients, and feasibility for both patients and health care providers were taken into account. Consensus was predefined as \u226575% agreement or disagreement with each statement.\n                    <jats:bold>Results:<\/jats:bold>\n                    The targeted literature review identified 14 fatigue-management strategies derived from 32 articles. These strategies were further refined and expanded by the expert advisors and modified Delphi panelists, who ultimately compiled a final list of 15 statements, each achieving \u226575% agreement. The 15 statements were grouped into 4 categories of fatigue-management strategies: exercise (eg, endurance, strength, aerobic, and resistance training), diet and nutrition (eg, hydration and healthy eating), clinical management (eg, counseling and support groups), and \u201cother strategies\u201d (eg, acupuncture and adopting good sleep habits).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    These recommendations and considerations provide practical guidance\u2014grounded in evidence and expert opinion\u2014for managing fatigue in patients with aPC, with the goal of improving quality of life. Future research should prioritize high-quality studies evaluating fatigue-management strategies in aPC, particularly in areas where published evidence remains limited.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7140","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:51:31Z","timestamp":1774968691000},"source":"Crossref","is-referenced-by-count":0,"title":["Consensus Recommendations for Disease- and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel"],"prefix":"10.6004","volume":"24","author":[{"given":"Stephen J.","family":"Freedland","sequence":"first","affiliation":[{"name":"Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA"},{"name":"Section of Urology, Durham VA Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Aronson","sequence":"additional","affiliation":[{"name":"Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA"},{"name":"Veterans Administration Medical Center, Greater Los Angeles Healthcare System, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Asher","sequence":"additional","affiliation":[{"name":"Department of Medicine and Physical Medicine and Rehabilitation and Patient and Family Support Program, Cedars-Sinai Cancer, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Golant","sequence":"additional","affiliation":[{"name":"Cancer Support Community, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Lemke","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Morris","sequence":"additional","affiliation":[{"name":"Urology Associates, P.C., Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Sutton","sequence":"additional","affiliation":[{"name":"Carolina Urologic Research Center, Myrtle Beach, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A.","family":"Thomson","sequence":"additional","affiliation":[{"name":"Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemyslaw","family":"Twardowski","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology, Saint John\u2019s Cancer Institute, Santa Monica, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Wefel","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology and Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri","family":"Winters-Stone","sequence":"additional","affiliation":[{"name":"Division of Oncological Sciences, Oregon Health & Science University, Portland, OR"},{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marty","family":"Chakoian","sequence":"additional","affiliation":[{"name":"Us TOO in Seattle, Prostate Cancer Support, Education, and Advocacy, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Wells","sequence":"additional","affiliation":[{"name":"IQVIA, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"ElSouda","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc., Northbrook, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Turnbull","sequence":"additional","affiliation":[{"name":"IQVIA, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Buzaglo","sequence":"additional","affiliation":[{"name":"IQVIA, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Mobley","sequence":"additional","affiliation":[{"name":"IQVIA, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Cohen","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc., Northbrook, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hogue","sequence":"additional","affiliation":[{"name":"Aesara, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader","family":"El-Chaar","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc., Northbrook, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maelys","family":"Touya","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc., Northbrook, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Ann Oncol","first-page":"713","article-title":"Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment","volume":"31","author":"Fabi A","year":"2020","unstructured":"Fabi A, Bhargava R, Fatigoni S,  Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann Oncol 2020;31:713\u2013723."},{"key":"B2","series-title":"Nat Rev Clin Oncol","first-page":"597","article-title":"Cancer-related fatigue\u2014mechanisms, risk factors, and treatments","volume":"11","author":"Bower JE.","year":"2014","unstructured":"Bower JE. Cancer-related fatigue\u2014mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 2014;11:597\u2013609."},{"key":"B3","series-title":"Support Care Cancer","first-page":"1761","article-title":"The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature","volume":"21","author":"Langston B","year":"2013","unstructured":"Langston B, Armes J, Levy A,  The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer 2013;21:1761\u20131771."},{"key":"B4","series-title":"BMC Urol","first-page":"92","article-title":"Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL study","volume":"19","author":"Rodr\u00edguez Antol\u00edn A","year":"2019","unstructured":"Rodr\u00edguez Antol\u00edn A, Mart\u00ednez-Pi\u00f1eiro L, Jim\u00e9nez Romero ME,  Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL study. BMC Urol 2019;19:92."},{"key":"B5","series-title":"Eur Urol Open Sci","first-page":"119","article-title":"Fatigue in prostate cancer: a roundtable discussion and thematic literature review","volume":"63","author":"Cornford P","year":"2024","unstructured":"Cornford P, Robijn E, Rogers E,  Fatigue in prostate cancer: a roundtable discussion and thematic literature review. Eur Urol Open Sci 2024;63:119\u2013125."},{"key":"B6","series-title":"Clin Genitourin Cancer","first-page":"102209","article-title":"Fatigue management in advanced prostate cancer: real-world insights from qualitative interviews with patients","volume":"22","author":"Freedland SJ","year":"2024","unstructured":"Freedland SJ, Chakoian M, Wells T,  Fatigue management in advanced prostate cancer: real-world insights from qualitative interviews with patients. Clin Genitourin Cancer 2024;22:102209."},{"key":"B7","series-title":"Eur Urol","first-page":"293","article-title":"Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial","volume":"72","author":"Taaffe DR","year":"2017","unstructured":"Taaffe DR, Newton RU, Spry N,  Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol 2017;72:293\u2013299."},{"key":"B8","series-title":"Ann Oncol","first-page":"1542","article-title":"Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy","volume":"23","author":"Storey DJ","year":"2012","unstructured":"Storey DJ, McLaren DB, Atkinson MA,  Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol 2012;23:1542\u20131549."},{"key":"B9","series-title":"N Engl J Med","first-page":"424","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer TM","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE,  Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424\u2013433."},{"key":"B10","series-title":"N Engl J Med","first-page":"1187","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher HI","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F,  Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187\u20131197."},{"key":"B11","series-title":"Res Rep Urol","first-page":"9","article-title":"How to improve the quality of life of patients with prostate cancer treated with hormone therapy?","volume":"15","author":"Turco F","year":"2023","unstructured":"Turco F, Lavinia DP, Chiara P,  How to improve the quality of life of patients with prostate cancer treated with hormone therapy? Res Rep Urol 2023;15:9\u201326."},{"key":"B12","series-title":"J Natl Cancer Inst","first-page":"583","article-title":"Active surveillance for prostate cancer: how active is too active?","volume":"117","author":"Tosoian JJ.","year":"2025","unstructured":"Tosoian JJ. Active surveillance for prostate cancer: how active is too active? J Natl Cancer Inst 2025;117:583\u2013585."},{"key":"B13","article-title":"Modern active surveillance in low- and intermediate-risk prostate cancer without re-biopsy","author":"Lakes J","unstructured":"Lakes J, Al-Monajjed R, Busshoff I,  Modern active surveillance in low- and intermediate-risk prostate cancer without re-biopsy. Prostate Cancer Prostatic Dis. Published online September 14, 2025. doi:10.1038\/s41391-025-01010-6"},{"key":"B14","series-title":"Curr Med Res Opin","first-page":"417","article-title":"Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan","volume":"38","author":"Iguchi T","year":"2022","unstructured":"Iguchi T, Nakamura Y, Akiyama T,  Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan. Curr Med Res Opin 2022;38:417\u2013426."},{"key":"B15","series-title":"J Clin Oncol","first-page":"2456","article-title":"Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update","volume":"42","author":"Bower JE","year":"2024","unstructured":"Bower JE, Lacchetti C, Alici Y,  Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update. J Clin Oncol 2024;42:2456\u20132487."},{"key":"B16","article-title":"NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 1.2026","author":"Jankowski C","unstructured":"Jankowski C, Banerjee C, Aranha O,  NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 1.2026. Accessed December 18, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B17","series-title":"J Clin Oncol","first-page":"2491","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline","volume":"40","author":"Ligibel JA","year":"2022","unstructured":"Ligibel JA, Bohlke K, May AM,  Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol 2022;40:2491\u20132507."},{"key":"B18","series-title":"J Urol","first-page":"1082","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline","volume":"209","author":"Lowrance W","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF,  Updates to advanced prostate cancer: AUA\/SUO guideline. J Urol 2023;209:1082\u20131090."},{"key":"B19","series-title":"JCO Oncol Pract","first-page":"783","article-title":"Management of advanced prostate cancer in clinical practice: real-world answers to challenging dilemmas","volume":"16","author":"Mar N","year":"2020","unstructured":"Mar N, Kalebasty AR, Uchio EM. Management of advanced prostate cancer in clinical practice: real-world answers to challenging dilemmas. JCO Oncol Pract 2020;16:783\u2013789."},{"key":"B20","series-title":"J Clin Oncol","first-page":"1148","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher HI","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I,  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148\u20131159."},{"key":"B21","article-title":"Scottish Intercollegiate Guidelines Network SIGN Grading System","unstructured":"Healthcare Improvement Scotland. Scottish Intercollegiate Guidelines Network SIGN Grading System. Accessed December 11, 2024. Available at: https:\/\/www.sign.ac.uk\/assets\/sign_grading_system_1999_2012.pdf"},{"key":"B22","series-title":"Medicine (Baltimore)","first-page":"e32829","article-title":"Use of Delphi in health sciences research: a narrative review","volume":"102","author":"Shang Z.","year":"2023","unstructured":"Shang Z. Use of Delphi in health sciences research: a narrative review. Medicine (Baltimore) 2023;102:e32829."},{"key":"B23","series-title":"J Healthc Leadersh","first-page":"63","article-title":"An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19","volume":"14","author":"Broder MS","year":"2022","unstructured":"Broder MS, Gibbs SN, Yermilov I. An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19. J Healthc Leadersh 2022;14:63\u201370."},{"key":"B24","series-title":"Palliat Med","first-page":"684","article-title":"Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review","volume":"31","author":"J\u00fcnger S","year":"2017","unstructured":"J\u00fcnger S, Payne SA, Brine J,  Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med 2017;31:684\u2013706."},{"key":"B25","series-title":"Technol Forecast Soc Change","first-page":"120484","article-title":"Consensus in the Delphi method: what makes a decision change?","volume":"163","author":"Barrios M","year":"2021","unstructured":"Barrios M, Guilera G, Nu\u00f1o L, G\u00f3mez-Benito J. Consensus in the Delphi method: what makes a decision change? Technol Forecast Soc Change 2021;163:120484."},{"key":"B26","series-title":"J Clin Oncol","first-page":"1653","article-title":"Resistance exercise in men receiving androgen deprivation therapy for prostate cancer","volume":"21","author":"Segal RJ","year":"2003","unstructured":"Segal RJ, Reid RD, Courneya KS,  Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003;21:1653\u20131659."},{"key":"B27","series-title":"J Clin Oncol","first-page":"344","article-title":"Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer","volume":"27","author":"Segal RJ","year":"2009","unstructured":"Segal RJ, Reid RD, Courneya KS,  Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009;27:344\u2013351."},{"key":"B28","series-title":"Int J Nurs Pract","first-page":"e12883","article-title":"Effect of the exercise programme on the quality of life of prostate cancer survivors: a randomized controlled trial","volume":"27","author":"Mardani A","year":"2021","unstructured":"Mardani A, Pedram Razi S, Mazaheri R,  Effect of the exercise programme on the quality of life of prostate cancer survivors: a randomized controlled trial. Int J Nurs Pract 2021;27:e12883."},{"key":"B29","series-title":"Arch Phys Med Rehabil","first-page":"1416","article-title":"Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy","volume":"88","author":"Monga U","year":"2007","unstructured":"Monga U, Garber SL, Thornby J,  Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil 2007;88:1416\u20131422."},{"key":"B30","series-title":"Med Sci Sports Exerc","first-page":"2375","article-title":"Exercise guidelines for cancer survivors: consensus statement from International Multidisciplinary Roundtable","volume":"51","author":"Campbell KL","year":"2019","unstructured":"Campbell KL, Winters-Stone KM, Wiskemann J,  Exercise guidelines for cancer survivors: consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc 2019;51:2375\u20132390."},{"key":"B31","series-title":"JCO Oncol Pract","first-page":"e697","article-title":"Exercise recommendation for people with bone metastases: expert consensus for health care providers and exercise professionals","volume":"18","author":"Campbell KL","year":"2022","unstructured":"Campbell KL, Cormie P, Weller S,  Exercise recommendation for people with bone metastases: expert consensus for health care providers and exercise professionals. JCO Oncol Pract 2022;18:e697\u2013709."},{"key":"B32","series-title":"Pol Arch Intern Med","first-page":"25","article-title":"Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer. A randomized controlled trial of a 12-month exercise program","volume":"127","author":"Hojan K","year":"2017","unstructured":"Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, Milecki P. Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer. A randomized controlled trial of a 12-month exercise program. Pol Arch Intern Med 2017;127:25\u201335."},{"key":"B33","series-title":"Eur J Phys Rehabil Med","first-page":"489","article-title":"Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study","volume":"52","author":"Hojan K","year":"2016","unstructured":"Hojan K, Kwiatkowska-Borowczyk E, Leporowska E,  Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study. Eur J Phys Rehabil Med 2016;52:489\u2013501."},{"key":"B34","series-title":"BJU Int","first-page":"256","article-title":"Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial","volume":"115","author":"Cormie P","year":"2015","unstructured":"Cormie P, Galv\u00e3o DA, Spry N,  Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int 2015;115:256\u2013266."},{"key":"B35","series-title":"Clin Nutr","first-page":"245","article-title":"Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial","volume":"40","author":"Baguley BJ","year":"2021","unstructured":"Baguley BJ, Skinner TL, Jenkins DG, Wright ORL. Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial. Clin Nutr 2021;40:245\u2013254."},{"key":"B36","article-title":"Xtandi capsules. Prescribing information. Astellas; 2018","unstructured":"Xtandi capsules. Prescribing information. Astellas; 2018. Accessed December 18, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203415s014lbl.pdf"},{"key":"B37","article-title":"Erleada tablets. Prescribing information. Janssen Products, LP; 2021","unstructured":"Erleada tablets. Prescribing information. Janssen Products, LP; 2021. Accessed December 18, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210951s005lbl.pdf"},{"key":"B38","article-title":"NUBEQA tablets","unstructured":"NUBEQA tablets. Prescribing information. Bayer; 2019. Accessed December 18, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf"},{"key":"B39","series-title":"J Clin Oncol","first-page":"4651","article-title":"Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer","volume":"26","author":"Espie CA","year":"2008","unstructured":"Espie CA, Fleming L, Cassidy J,  Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008;26:4651\u20134658."},{"key":"B40","series-title":"Oncologist","first-page":"1122","article-title":"Is increasing physical activity necessary to diminish fatigue during cancer treatment? Comparing cognitive behavior therapy and a brief nursing intervention with usual care in a multicenter randomized controlled trial","volume":"15","author":"Goedendorp MM","year":"2010","unstructured":"Goedendorp MM, Peters ME, Gielissen MF,  Is increasing physical activity necessary to diminish fatigue during cancer treatment? Comparing cognitive behavior therapy and a brief nursing intervention with usual care in a multicenter randomized controlled trial. Oncologist 2010;15:1122\u20131132."},{"key":"B41","series-title":"Sleep Med Rev","first-page":"101764","article-title":"The effect of caffeine on subsequent sleep: a systematic review and meta-analysis","volume":"69","author":"Gardiner C","year":"2023","unstructured":"Gardiner C, Weakley J, Burke LM,  The effect of caffeine on subsequent sleep: a systematic review and meta-analysis. Sleep Med Rev 2023;69:101764."},{"key":"B42","series-title":"J Psychiatr Res","first-page":"196","article-title":"Blocking nocturnal blue light for insomnia: a randomized controlled trial","volume":"96","author":"Shechter A","year":"2018","unstructured":"Shechter A, Kim EW, St-Onge MP, Westwood AJ. Blocking nocturnal blue light for insomnia: a randomized controlled trial. J Psychiatr Res 2018;96:196\u2013202."},{"key":"B43","series-title":"Integr Cancer Ther","first-page":"409","article-title":"Effects of a 15-month supervised exercise program on physical and psychological outcomes in prostate cancer patients following prostatectomy: the ProRehab Study","volume":"14","author":"Zopf EM","year":"2015","unstructured":"Zopf EM, Bloch W, Machtens S,  Effects of a 15-month supervised exercise program on physical and psychological outcomes in prostate cancer patients following prostatectomy: the ProRehab Study. Integr Cancer Ther 2015;14:409\u2013418."},{"key":"B44","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"647","article-title":"Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study","volume":"20","author":"Bourke L","year":"2011","unstructured":"Bourke L, Doll H, Crank H,  Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomarkers Prev 2011;20:647\u2013657."},{"key":"B45","series-title":"Am J Clin Oncol","first-page":"350","article-title":"Prospective evaluation of a 12-week walking exercise program and its effect on fatigue in prostate cancer patients undergoing radical external beam radiotherapy","volume":"34","author":"Truong PT","year":"2011","unstructured":"Truong PT, Gaul CA, McDonald RE,  Prospective evaluation of a 12-week walking exercise program and its effect on fatigue in prostate cancer patients undergoing radical external beam radiotherapy. Am J Clin Oncol 2011;34:350\u2013355."},{"key":"B46","series-title":"BJU Int","first-page":"28","article-title":"Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial","volume":"125","author":"Ndjavera W","year":"2020","unstructured":"Ndjavera W, Orange ST, O\u2019Doherty AF,  Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial. BJU Int 2020;125:28\u201337."},{"key":"B47","series-title":"J Sport Exerc Psychol","first-page":"118","article-title":"Benefits of a physical activity intervention for men with prostate cancer","volume":"29","author":"Culos-Reed SN","year":"2007","unstructured":"Culos-Reed SN, Robinson JL, Lau H,  Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol 2007;29:118\u2013127."},{"key":"B48","series-title":"Biomed Res Int","first-page":"3989286.","article-title":"Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy","volume":"2016","author":"Charalambous A","year":"2016","unstructured":"Charalambous A, Kouta C. Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy. Biomed Res Int 2016;2016:3989286."},{"key":"B49","series-title":"J Geriatr Oncol","first-page":"101397","article-title":"Symptom experiences of older adults during treatment for metastatic prostate cancer: a qualitative investigation","volume":"14","author":"Parthipan M","year":"2023","unstructured":"Parthipan M, Feng G, Toledano N,  Symptom experiences of older adults during treatment for metastatic prostate cancer: a qualitative investigation. J Geriatr Oncol 2023;14:101397."},{"key":"B50","series-title":"Eur Urol Oncol","first-page":"1376","article-title":"A prospective randomised trial to determine the effect of a reduced versus standard dose of enzalutamide on side effects in frail patients with prostate cancer","volume":"7","author":"Boerrigter E","year":"2024","unstructured":"Boerrigter E, Overbeek JK, Benoist GE,  A prospective randomised trial to determine the effect of a reduced versus standard dose of enzalutamide on side effects in frail patients with prostate cancer. Eur Urol Oncol 2024;7:1376\u20131383."},{"key":"B51","series-title":"Urol Oncol","first-page":"233.e15\u201320.","article-title":"Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer","volume":"39","author":"Miura R","year":"2021","unstructured":"Miura R, Hirabatake M, Irie K,  Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer. Urol Oncol 2021;39:233.e15\u201320."},{"key":"B52","series-title":"Int J Clin Oncol","first-page":"1155","article-title":"Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study","volume":"21","author":"Terada N","year":"2016","unstructured":"Terada N, Akamatsu S, Okada Y,  Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. Int J Clin Oncol 2016;21:1155\u20131161."},{"key":"B1","series-title":"Ann Oncol","first-page":"713","article-title":"Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment","volume":"31","author":"Fabi A","year":"2020","unstructured":"Fabi A, Bhargava R, Fatigoni S,  Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann Oncol 2020;31:713\u2013723."},{"key":"B2","series-title":"Nat Rev Clin Oncol","first-page":"597","article-title":"Cancer-related fatigue\u2014mechanisms, risk factors, and treatments","volume":"11","author":"Bower JE.","year":"2014","unstructured":"Bower JE. Cancer-related fatigue\u2014mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 2014;11:597\u2013609."},{"key":"B3","series-title":"Support Care Cancer","first-page":"1761","article-title":"The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature","volume":"21","author":"Langston B","year":"2013","unstructured":"Langston B, Armes J, Levy A,  The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer 2013;21:1761\u20131771."},{"key":"B4","series-title":"BMC Urol","first-page":"92","article-title":"Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL study","volume":"19","author":"Rodr\u00edguez Antol\u00edn A","year":"2019","unstructured":"Rodr\u00edguez Antol\u00edn A, Mart\u00ednez-Pi\u00f1eiro L, Jim\u00e9nez Romero ME,  Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL study. BMC Urol 2019;19:92."},{"key":"B5","series-title":"Eur Urol Open Sci","first-page":"119","article-title":"Fatigue in prostate cancer: a roundtable discussion and thematic literature review","volume":"63","author":"Cornford P","year":"2024","unstructured":"Cornford P, Robijn E, Rogers E,  Fatigue in prostate cancer: a roundtable discussion and thematic literature review. Eur Urol Open Sci 2024;63:119\u2013125."},{"key":"B6","series-title":"Clin Genitourin Cancer","first-page":"102209","article-title":"Fatigue management in advanced prostate cancer: real-world insights from qualitative interviews with patients","volume":"22","author":"Freedland SJ","year":"2024","unstructured":"Freedland SJ, Chakoian M, Wells T,  Fatigue management in advanced prostate cancer: real-world insights from qualitative interviews with patients. Clin Genitourin Cancer 2024;22:102209."},{"key":"B7","series-title":"Eur Urol","first-page":"293","article-title":"Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial","volume":"72","author":"Taaffe DR","year":"2017","unstructured":"Taaffe DR, Newton RU, Spry N,  Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol 2017;72:293\u2013299."},{"key":"B8","series-title":"Ann Oncol","first-page":"1542","article-title":"Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy","volume":"23","author":"Storey DJ","year":"2012","unstructured":"Storey DJ, McLaren DB, Atkinson MA,  Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol 2012;23:1542\u20131549."},{"key":"B9","series-title":"N Engl J Med","first-page":"424","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer TM","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE,  Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424\u2013433."},{"key":"B10","series-title":"N Engl J Med","first-page":"1187","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher HI","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F,  Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187\u20131197."},{"key":"B11","series-title":"Res Rep Urol","first-page":"9","article-title":"How to improve the quality of life of patients with prostate cancer treated with hormone therapy?","volume":"15","author":"Turco F","year":"2023","unstructured":"Turco F, Lavinia DP, Chiara P,  How to improve the quality of life of patients with prostate cancer treated with hormone therapy? Res Rep Urol 2023;15:9\u201326."},{"key":"B12","series-title":"J Natl Cancer Inst","first-page":"583","article-title":"Active surveillance for prostate cancer: how active is too active?","volume":"117","author":"Tosoian JJ.","year":"2025","unstructured":"Tosoian JJ. Active surveillance for prostate cancer: how active is too active? J Natl Cancer Inst 2025;117:583\u2013585."},{"key":"B13","article-title":"Modern active surveillance in low- and intermediate-risk prostate cancer without re-biopsy","author":"Lakes J","unstructured":"Lakes J, Al-Monajjed R, Busshoff I,  Modern active surveillance in low- and intermediate-risk prostate cancer without re-biopsy. Prostate Cancer Prostatic Dis. Published online September 14, 2025. doi:10.1038\/s41391-025-01010-6"},{"key":"B14","series-title":"Curr Med Res Opin","first-page":"417","article-title":"Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan","volume":"38","author":"Iguchi T","year":"2022","unstructured":"Iguchi T, Nakamura Y, Akiyama T,  Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan. Curr Med Res Opin 2022;38:417\u2013426."},{"key":"B15","series-title":"J Clin Oncol","first-page":"2456","article-title":"Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update","volume":"42","author":"Bower JE","year":"2024","unstructured":"Bower JE, Lacchetti C, Alici Y,  Management of fatigue in adult survivors of cancer: ASCO-Society for Integrative Oncology guideline update. J Clin Oncol 2024;42:2456\u20132487."},{"key":"B16","article-title":"NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 1.2026","author":"Jankowski C","unstructured":"Jankowski C, Banerjee C, Aranha O,  NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 1.2026. Accessed December 18, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B17","series-title":"J Clin Oncol","first-page":"2491","article-title":"Exercise, diet, and weight management during cancer treatment: ASCO guideline","volume":"40","author":"Ligibel JA","year":"2022","unstructured":"Ligibel JA, Bohlke K, May AM,  Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol 2022;40:2491\u20132507."},{"key":"B18","series-title":"J Urol","first-page":"1082","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline","volume":"209","author":"Lowrance W","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF,  Updates to advanced prostate cancer: AUA\/SUO guideline. J Urol 2023;209:1082\u20131090."},{"key":"B19","series-title":"JCO Oncol Pract","first-page":"783","article-title":"Management of advanced prostate cancer in clinical practice: real-world answers to challenging dilemmas","volume":"16","author":"Mar N","year":"2020","unstructured":"Mar N, Kalebasty AR, Uchio EM. Management of advanced prostate cancer in clinical practice: real-world answers to challenging dilemmas. JCO Oncol Pract 2020;16:783\u2013789."},{"key":"B20","series-title":"J Clin Oncol","first-page":"1148","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher HI","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I,  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148\u20131159."},{"key":"B21","article-title":"Scottish Intercollegiate Guidelines Network SIGN Grading System","unstructured":"Healthcare Improvement Scotland. Scottish Intercollegiate Guidelines Network SIGN Grading System. Accessed December 11, 2024. Available at: https:\/\/www.sign.ac.uk\/assets\/sign_grading_system_1999_2012.pdf"},{"key":"B22","series-title":"Medicine (Baltimore)","first-page":"e32829","article-title":"Use of Delphi in health sciences research: a narrative review","volume":"102","author":"Shang Z.","year":"2023","unstructured":"Shang Z. Use of Delphi in health sciences research: a narrative review. Medicine (Baltimore) 2023;102:e32829."},{"key":"B23","series-title":"J Healthc Leadersh","first-page":"63","article-title":"An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19","volume":"14","author":"Broder MS","year":"2022","unstructured":"Broder MS, Gibbs SN, Yermilov I. An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19. J Healthc Leadersh 2022;14:63\u201370."},{"key":"B24","series-title":"Palliat Med","first-page":"684","article-title":"Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review","volume":"31","author":"J\u00fcnger S","year":"2017","unstructured":"J\u00fcnger S, Payne SA, Brine J,  Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med 2017;31:684\u2013706."},{"key":"B25","series-title":"Technol Forecast Soc Change","first-page":"120484","article-title":"Consensus in the Delphi method: what makes a decision change?","volume":"163","author":"Barrios M","year":"2021","unstructured":"Barrios M, Guilera G, Nu\u00f1o L, G\u00f3mez-Benito J. Consensus in the Delphi method: what makes a decision change? Technol Forecast Soc Change 2021;163:120484."},{"key":"B26","series-title":"J Clin Oncol","first-page":"1653","article-title":"Resistance exercise in men receiving androgen deprivation therapy for prostate cancer","volume":"21","author":"Segal RJ","year":"2003","unstructured":"Segal RJ, Reid RD, Courneya KS,  Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003;21:1653\u20131659."},{"key":"B27","series-title":"J Clin Oncol","first-page":"344","article-title":"Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer","volume":"27","author":"Segal RJ","year":"2009","unstructured":"Segal RJ, Reid RD, Courneya KS,  Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009;27:344\u2013351."},{"key":"B28","series-title":"Int J Nurs Pract","first-page":"e12883","article-title":"Effect of the exercise programme on the quality of life of prostate cancer survivors: a randomized controlled trial","volume":"27","author":"Mardani A","year":"2021","unstructured":"Mardani A, Pedram Razi S, Mazaheri R,  Effect of the exercise programme on the quality of life of prostate cancer survivors: a randomized controlled trial. Int J Nurs Pract 2021;27:e12883."},{"key":"B29","series-title":"Arch Phys Med Rehabil","first-page":"1416","article-title":"Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy","volume":"88","author":"Monga U","year":"2007","unstructured":"Monga U, Garber SL, Thornby J,  Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil 2007;88:1416\u20131422."},{"key":"B30","series-title":"Med Sci Sports Exerc","first-page":"2375","article-title":"Exercise guidelines for cancer survivors: consensus statement from International Multidisciplinary Roundtable","volume":"51","author":"Campbell KL","year":"2019","unstructured":"Campbell KL, Winters-Stone KM, Wiskemann J,  Exercise guidelines for cancer survivors: consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc 2019;51:2375\u20132390."},{"key":"B31","series-title":"JCO Oncol Pract","first-page":"e697","article-title":"Exercise recommendation for people with bone metastases: expert consensus for health care providers and exercise professionals","volume":"18","author":"Campbell KL","year":"2022","unstructured":"Campbell KL, Cormie P, Weller S,  Exercise recommendation for people with bone metastases: expert consensus for health care providers and exercise professionals. JCO Oncol Pract 2022;18:e697\u2013709."},{"key":"B32","series-title":"Pol Arch Intern Med","first-page":"25","article-title":"Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer. A randomized controlled trial of a 12-month exercise program","volume":"127","author":"Hojan K","year":"2017","unstructured":"Hojan K, Kwiatkowska-Borowczyk E, Leporowska E, Milecki P. Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer. A randomized controlled trial of a 12-month exercise program. Pol Arch Intern Med 2017;127:25\u201335."},{"key":"B33","series-title":"Eur J Phys Rehabil Med","first-page":"489","article-title":"Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study","volume":"52","author":"Hojan K","year":"2016","unstructured":"Hojan K, Kwiatkowska-Borowczyk E, Leporowska E,  Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study. Eur J Phys Rehabil Med 2016;52:489\u2013501."},{"key":"B34","series-title":"BJU Int","first-page":"256","article-title":"Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial","volume":"115","author":"Cormie P","year":"2015","unstructured":"Cormie P, Galv\u00e3o DA, Spry N,  Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int 2015;115:256\u2013266."},{"key":"B35","series-title":"Clin Nutr","first-page":"245","article-title":"Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial","volume":"40","author":"Baguley BJ","year":"2021","unstructured":"Baguley BJ, Skinner TL, Jenkins DG, Wright ORL. Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial. Clin Nutr 2021;40:245\u2013254."},{"key":"B36","article-title":"Xtandi capsules. Prescribing information. Astellas; 2018","unstructured":"Xtandi capsules. Prescribing information. Astellas; 2018. Accessed December 18, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203415s014lbl.pdf"},{"key":"B37","article-title":"Erleada tablets. Prescribing information. Janssen Products, LP; 2021","unstructured":"Erleada tablets. Prescribing information. Janssen Products, LP; 2021. Accessed December 18, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210951s005lbl.pdf"},{"key":"B38","article-title":"NUBEQA tablets","unstructured":"NUBEQA tablets. Prescribing information. Bayer; 2019. Accessed December 18, 2024. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf"},{"key":"B39","series-title":"J Clin Oncol","first-page":"4651","article-title":"Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer","volume":"26","author":"Espie CA","year":"2008","unstructured":"Espie CA, Fleming L, Cassidy J,  Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008;26:4651\u20134658."},{"key":"B40","series-title":"Oncologist","first-page":"1122","article-title":"Is increasing physical activity necessary to diminish fatigue during cancer treatment? Comparing cognitive behavior therapy and a brief nursing intervention with usual care in a multicenter randomized controlled trial","volume":"15","author":"Goedendorp MM","year":"2010","unstructured":"Goedendorp MM, Peters ME, Gielissen MF,  Is increasing physical activity necessary to diminish fatigue during cancer treatment? Comparing cognitive behavior therapy and a brief nursing intervention with usual care in a multicenter randomized controlled trial. Oncologist 2010;15:1122\u20131132."},{"key":"B41","series-title":"Sleep Med Rev","first-page":"101764","article-title":"The effect of caffeine on subsequent sleep: a systematic review and meta-analysis","volume":"69","author":"Gardiner C","year":"2023","unstructured":"Gardiner C, Weakley J, Burke LM,  The effect of caffeine on subsequent sleep: a systematic review and meta-analysis. Sleep Med Rev 2023;69:101764."},{"key":"B42","series-title":"J Psychiatr Res","first-page":"196","article-title":"Blocking nocturnal blue light for insomnia: a randomized controlled trial","volume":"96","author":"Shechter A","year":"2018","unstructured":"Shechter A, Kim EW, St-Onge MP, Westwood AJ. Blocking nocturnal blue light for insomnia: a randomized controlled trial. J Psychiatr Res 2018;96:196\u2013202."},{"key":"B43","series-title":"Integr Cancer Ther","first-page":"409","article-title":"Effects of a 15-month supervised exercise program on physical and psychological outcomes in prostate cancer patients following prostatectomy: the ProRehab Study","volume":"14","author":"Zopf EM","year":"2015","unstructured":"Zopf EM, Bloch W, Machtens S,  Effects of a 15-month supervised exercise program on physical and psychological outcomes in prostate cancer patients following prostatectomy: the ProRehab Study. Integr Cancer Ther 2015;14:409\u2013418."},{"key":"B44","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"647","article-title":"Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study","volume":"20","author":"Bourke L","year":"2011","unstructured":"Bourke L, Doll H, Crank H,  Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomarkers Prev 2011;20:647\u2013657."},{"key":"B45","series-title":"Am J Clin Oncol","first-page":"350","article-title":"Prospective evaluation of a 12-week walking exercise program and its effect on fatigue in prostate cancer patients undergoing radical external beam radiotherapy","volume":"34","author":"Truong PT","year":"2011","unstructured":"Truong PT, Gaul CA, McDonald RE,  Prospective evaluation of a 12-week walking exercise program and its effect on fatigue in prostate cancer patients undergoing radical external beam radiotherapy. Am J Clin Oncol 2011;34:350\u2013355."},{"key":"B46","series-title":"BJU Int","first-page":"28","article-title":"Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial","volume":"125","author":"Ndjavera W","year":"2020","unstructured":"Ndjavera W, Orange ST, O\u2019Doherty AF,  Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial. BJU Int 2020;125:28\u201337."},{"key":"B47","series-title":"J Sport Exerc Psychol","first-page":"118","article-title":"Benefits of a physical activity intervention for men with prostate cancer","volume":"29","author":"Culos-Reed SN","year":"2007","unstructured":"Culos-Reed SN, Robinson JL, Lau H,  Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol 2007;29:118\u2013127."},{"key":"B48","series-title":"Biomed Res Int","first-page":"3989286.","article-title":"Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy","volume":"2016","author":"Charalambous A","year":"2016","unstructured":"Charalambous A, Kouta C. Cancer related fatigue and quality of life in patients with advanced prostate cancer undergoing chemotherapy. Biomed Res Int 2016;2016:3989286."},{"key":"B49","series-title":"J Geriatr Oncol","first-page":"101397","article-title":"Symptom experiences of older adults during treatment for metastatic prostate cancer: a qualitative investigation","volume":"14","author":"Parthipan M","year":"2023","unstructured":"Parthipan M, Feng G, Toledano N,  Symptom experiences of older adults during treatment for metastatic prostate cancer: a qualitative investigation. J Geriatr Oncol 2023;14:101397."},{"key":"B50","series-title":"Eur Urol Oncol","first-page":"1376","article-title":"A prospective randomised trial to determine the effect of a reduced versus standard dose of enzalutamide on side effects in frail patients with prostate cancer","volume":"7","author":"Boerrigter E","year":"2024","unstructured":"Boerrigter E, Overbeek JK, Benoist GE,  A prospective randomised trial to determine the effect of a reduced versus standard dose of enzalutamide on side effects in frail patients with prostate cancer. Eur Urol Oncol 2024;7:1376\u20131383."},{"key":"B51","series-title":"Urol Oncol","first-page":"233.e15\u201320.","article-title":"Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer","volume":"39","author":"Miura R","year":"2021","unstructured":"Miura R, Hirabatake M, Irie K,  Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer. Urol Oncol 2021;39:233.e15\u201320."},{"key":"B52","series-title":"Int J Clin Oncol","first-page":"1155","article-title":"Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study","volume":"21","author":"Terada N","year":"2016","unstructured":"Terada N, Akamatsu S, Okada Y,  Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. Int J Clin Oncol 2016;21:1155\u20131161."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/5\/article-e257140.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/5\/article-e257140.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/5\/article-e257140.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:32:44Z","timestamp":1778754764000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/5\/article-e257140.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":104,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7140","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}